Barclays PLC raised its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 13.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,228,360 shares of the company's stock after purchasing an additional 377,195 shares during the quarter. Barclays PLC owned 0.87% of Standard BioTools worth $6,231,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Wolverine Trading LLC bought a new position in shares of Standard BioTools in the 3rd quarter valued at about $27,000. Xponance Inc. purchased a new stake in Standard BioTools during the second quarter valued at approximately $34,000. Nisa Investment Advisors LLC boosted its holdings in shares of Standard BioTools by 433.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company's stock worth $35,000 after purchasing an additional 14,732 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in shares of Standard BioTools in the 2nd quarter worth approximately $39,000. Finally, Creative Planning bought a new position in shares of Standard BioTools during the 3rd quarter valued at approximately $39,000. 53.74% of the stock is owned by hedge funds and other institutional investors.
Standard BioTools Stock Up 0.8 %
NASDAQ:LAB traded up $0.02 during mid-day trading on Friday, hitting $2.00. 4,656,522 shares of the stock traded hands, compared to its average volume of 2,399,177. Standard BioTools Inc. has a 52 week low of $1.21 and a 52 week high of $3.04. The stock has a market capitalization of $744.52 million, a price-to-earnings ratio of -2.82 and a beta of 1.61. The firm's 50 day moving average is $1.87 and its two-hundred day moving average is $1.94.
Analyst Ratings Changes
Separately, TD Cowen dropped their price objective on shares of Standard BioTools from $2.75 to $2.50 and set a "buy" rating for the company in a research note on Thursday, October 31st.
Check Out Our Latest Stock Analysis on Standard BioTools
About Standard BioTools
(
Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Further Reading
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
